About Stemtrix
About Stemtrix
About Stemtrix
About Stemtrix
About Stemtrix
About Stemtrix
About Stemtrix
About Stemtrix
Our mission is to bring to the market a group of drugs for the treatment of infectious diseases, which will allow: to avoid the development and block the existing mechanisms of resistance; reduce the virulence and size of pathogen populations
Our mission is to bring to the market a group of drugs for the treatment of infectious diseases, which will allow: to avoid the development and block the existing mechanisms of resistance; reduce the virulence and size of pathogen populations
Our mission is to bring to the market a group of drugs for the treatment of infectious diseases, which will allow: to avoid the development and block the existing mechanisms of resistance; reduce the virulence and size of pathogen populations
9+
9+
Years of Experience
Years of Experience
3+
3+
Countries
Countries
100%
100%
Client Satisfaction
Client Satisfaction
Our Team
Evgenii Koluga
25 years of entrepreneurial experience, management of innovative projects, creation and management of enterprises and financial institutions, IT patents.
Ph.D. CEO
Andrey Gaponov
Doctor, biotechnologist, specialist in the field of microbiology, entrepreneur, experience in sales of veterinary and medical preparations, international expert, more than 10 patents.
Ph.D. CRO, Scientific Director
Sergey Schurok
Entrepreneur, more than 20 years of experience in organizing the production and sales of veterinary drugs, experience in registration of veterinary and medicinal products, more than 5 patents.
COO, Chief Operating Officer
Our Team
Our Team
Evgenii Koluga
Evgenii Koluga
25 years of entrepreneurial experience, management of innovative projects, creation and management of enterprises and financial institutions, IT patents.
Ph.D. CEO
25 years of entrepreneurial experience, management of innovative projects, creation and management of enterprises and financial institutions, IT patents.
Ph.D. CEO
Andrey Gaponov
Andrey Gaponov
Doctor, biotechnologist, specialist in the field of microbiology, entrepreneur, experience in sales of veterinary and medical preparations, international expert, more than 10 patents.
Ph.D. CRO, Scientific Director
Doctor, biotechnologist, specialist in the field of microbiology, entrepreneur, experience in sales of veterinary and medical preparations, international expert, more than 10 patents.
Ph.D. CRO, Scientific Director
Sergey Schurok
Sergey Schurok
Entrepreneur, more than 20 years of experience in organizing the production and sales of veterinary drugs, experience in registration of veterinary and medicinal products, more than 5 patents.
COO, Chief Operating Officer
Entrepreneur, more than 20 years of experience in organizing the production and sales of veterinary drugs, experience in registration of veterinary and medicinal products, more than 5 patents.
COO, Chief Operating Officer
Our competitive advantages
1
Innovations in the treatment of infectious diseases
Radical reduction in the use of antibiotics in veterinary medicine and medicine
2
Team competencies
Qualification of the team corresponds to the goals and objectives. Has a serious scientific and patent base, rich production and business competencies
3
Global product focus and markets
Products are extremely popular for people, animals and birds. The total market estimate for all veterinary drugs of the Stemtrix group is more than $ 10 billion
4
Global scalability of the technology
Some of the most important advantages are low cost, fast production organization and scalability.
4
Technology commercialization strategy
R&D, IP, registration of drugs & sales in Israel, EU, China, USA, Brazil, India and Mexico. Production in EU GMP, India.
Our competitive advantages
Our competitive advantages
1
Innovations in the treatment of infectious diseases
Radical reduction in the use of antibiotics in veterinary medicine and medicine
2
Team competencies
Qualification of the team corresponds to the goals and objectives. Has a serious scientific and patent base, rich production and business competencies
3
Global product focus and markets
Products are extremely popular for people, animals and birds. The total market estimate for all veterinary drugs of the Stemtrix group is more than $ 10 billion
4
Global scalability of the technology
Some of the most important advantages are low cost, fast production organization and scalability.
4
Technology commercialization strategy
R&D, IP, registration of drugs & sales in Israel, EU, China, USA, Brazil, India and Mexico. Production in EU GMP, India.
Stemtrix products portfolio
Stemtrix products portfolio
Stemtrix products
portfolio
Our medications can be used in the tretment of the large number of diseases:
gastrointestinal tract, urogenital pathways, skin, ear. Combination therapy is possible,
including the use of the drug and any antibacterial agent
Our medications can be used in the tretment of the large number of diseases:
gastrointestinal tract, urogenital pathways, skin, ear. Combination therapy is possible,
including the use of the drug and any antibacterial agent
Animal medicine
Animal medicine
Animal medicine
Animal medicine
Animal medicine
Animal medicine